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Mutations of the Uromodulin gene in MCKD type 2 patients
cluster in exon 4, which encodes three EGF-like domains.
Background. Autosomal-dominant medullary cystic kidney
disease type 2 (MCKD2) is a tubulointerstitial nephropathy that
causes renal salt wasting, hyperuricemia, gout, and end-stage re-
nal failure in the fifth decade of life. The chromosomal locus for
MCKD2 was localized on chromosome 16p12. Within this chro-
mosomal region, Uromodulin (UMOD) was located as a candi-
date gene. UMOD encodes the Tamm-Horsfall protein. By se-
quence analysis, one group formerly excluded UMOD as the
disease-causing gene. In contrast, recently, another group de-
scribed mutations in the UMOD gene as responsible for MCKD2
and familial juvenile hyperuricemic nephropathy (FJHN).
Methods. Haplotype analaysis for linkage to MCKD2 was
performed in 25 MCKD families. In the kindreds showing
linkage to the MCKD2 locus on chromosome 16p12, muta-
tional analysis of the UMOD gene was performed by exon
polymerase chain reaction (PCR) and direct sequencing.
Results. In 19 families, haplotype analysis was compatible
with linkage to the MCKD2 locus. All these kindreds were
examined for mutations in the UMOD gene. In three different
families, three novel heterozygous mutations in the UMOD
gene were found and segregated with the phenotype in affected
individuals. Mutations were found only in exon 4.
Conclusion. We confirm the UMOD gene as the disease-
causing gene for MCKD2. All three novel mutations were
found in the fourth exon of UMOD, in which all mutations
except one (this is located in the neighboring exon 5) published
so far are located. These data point to a specific role of exon 4
encoded sequence of UMOD in the generation of the MCKD2
renal phenotype.
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Medullary cystic kidney disease type 2 (MCKD2)
(OMIM 603860) includes clinical features of reduced
urinary concentration, salt wasting, and end-stage renal
failure. In contrast to MCKD1, in MCKD2, a more se-
vere phenotype concerning hyperuricemia and gout has
been described. Moreover, in MCKD2, an earlier median
age of onset has been reported (age of onset in MCKD2
is 32 years of age compared to 62 years in MCKD1) [1].
Otherwise, these two diseases are clinically undistinguish-
able. In MCKD, small corticomedullary cysts are com-
mon, but not always detected. Kidney size is normal or
slightly reduced. MCKD shows a renal histologic triad of
(1) tubular basement disintegration, (2) tubular atrophy
with cyst development at the corticomedullary border,
and (3) interstitial cell infiltration associated with fibrosis
[2]. Neither imaging results, nor pathologic findings, are
pathognomic for MCKD2. The condition shares clinical
and morphologic similarities to recessive juvenile neph-
ronophthisis (NPH) [3]. In contrast to juvenile onset in
NPH, end-stage renal failure in MCKD occurs in adult-
hood. Moreover NPH is inherited in an autosomal-reces-
sive pattern, whereas MCKD is autosomal-dominant.
Two loci for MCKD have been described: MCKD1
showed linkage to chromosome 1q21 in two Cypriot fam-
ilies [4] and MCKD2 was localized on chromosome 16p12
in an Italian family [1]. Two groups showed indepen-
dently that loci for familial juvenile hyperuremic ne-
phropathy (FJHN) and MCKD2 mapped to the same
chromosomal region on 16p12 [5, 6], assuming that FJHN
and MCKD2 might be different facets of the same dis-
ease caused by mutations in one and the same gene.
Later, an additional FJHN locus was mapped to a more
centromeric region [7] on chromosome 16, resulting in
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two different FJHN loci, which are overlapped by the
MCKD2 locus [8]. Two years after publication of the
chromosomal candidate region of MCKD2, Uromodulin
(UMOD) was published as excluded from representing
the disease-causing gene [9]. In contrast however, Hart
et al [10] later detected four different mutations in the
UMOD gene, indicating that this is the gene responsible
for FJHN and MCKD2.
UMOD encodes the Tamm-Horsfall protein (THP),
which is expressed primarily at the luminal side of renal
epithelial cells of the thick ascending loop of Henle and
of early distal convoluted tubules. THP is the most abun-
dant protein in the urine of humans [11]. Functional
roles of UMOD have been described in urinary tract
infections, in binding to complement factors, in myeloma
kidney, and nephrolithiasis [12–15]. The UMOD protein
contains (1) a zona pellucida domain (ZP), which is
necessary for polymerization into the supramolecular
structure of a filament, (2) an elastase-sensitive fragment
containing three calcium-binding epidermal growth fac-
tor (EGF)-like domains and a signal peptide, and (3)
a potential glycosyl-phosphatidylinositol (GPI)-anchor
cleavage site. UMOD is a transmembrane-bound pro-
tein, which can be secreted into the urine by cleavage
of the GPI-anchor [16].
We here report three novel mutations in UMOD and
confirm UMOD as the disease-causing gene. So far, eight
mutations published are located in exon 4 and one muta-
tion was found at the beginning of the neighboring exon
5 of the UMOD gene that encodes three EGF-like do-
mains [10, 17].
METHODS
Patients
We ascertained 25 MCKD families (224 individuals,
of which 84 were affected). Fourteen families were from
Germany, three from the United States, two each from
the United Kingdom, Hungary, and Turkey, respec-
tively, one each from Belgium and China, respectively.
The age at diagnosis, the age at onset of end-stage renal
disease (ESRD), hyperuricemia, imaging data, and biopsy
results were reviewed if available. Clinical criteria neces-
sary for inclusion were (1) compatibility of pedigree
with autosomal-dominant inheritance, (2) chronic renal
failure, (3) defective urine concentration (800 mOsm/L
after overnight dehydration) with polyuria (3 L/day),
and (4) at least one pedigree member with chronic renal
failure in whom renal biopsy showed tubulointerstitial
fibrosis with infiltrates, tubular atrophy, and thickening
of the tubular basement membrane. Optional clinical
criteria were normal or small-sized kidneys with occa-
sional small corticomedullary cysts. Hyperuricemia was
defined as serum uric acid concentration 1 SD greater
than the normal values for age and gender (both genders
5 to 10 years, 4.1  1 mg/dL; female, 12 years, 4.5  0.9
mg/dL; 15 years, 4.5  0.9 mg/dL; 18 years, 4.0  0.7
mg/dL; male, 12 years, 4.4  1.1 mg/dL; 15 years, 5.5 
1.1 mg/dL; 18 years, 6.2  0.8) [18].
The study was approved by the Ethics Committee of
the Albert-Ludwigs-University Freiburg and all partici-
pating family members provided informed consent.
Haplotype analysis
Genomic DNA was isolated by standard methods di-
rectly from blood samples using the QIAamp blood kit
(Qiagen, Valencia, CA, USA) or from blood lymphocytes
after Epstein-Barr virus (EBV) transformation. Haplo-
type analysis was performed in 224 individuals (including
84 affected individuals) and inferred in 18 additional
individuals (nine additional affected individuals), using
13 consecutive polymorphic microsatellite markers that
span the critical MCKD2 region in the following order:
cen-D16S3116-D16S401-D16S3113-D16S420-D16S417-
D16S412-D16-S3036-D16S3041-D16S3056-D16S501-
D16S499-D16S-3060-D16S764-tel. Fluorescently labeled
polymerase chain reaction (PCR) products were detected
by a Genetic Analyzer 3100 (Applied Biosystems, Foster
City, CA, USA) and were analyzed by the GENOTYPER
software.
Mutational analysis of the UMOD gene
Mutational analysis was performed by exon PCR
of the Uromodulin gene. Primer sequences were deter-
mined using the UCSC sequence (November 2002
freeze) encompassing the coding sequence of UMOD
[19]. The following primers and conditions were em-
ployed: exon 3, 5-CAATCAAAGCACTCCTTCCAG-
3 and 5-GACAGGTGCTACATTGCTTCC-3; exon
4 was divided into two different overlapping parts: exon
4a, 5-CCTGGAGAATGAGGGAAGG-3 and 5-CTG
GACGAGTACTGGCGC-3; exon 4b, 5-GGCAGCT
ACTTGTGCGTATG-3 and 5-CTCTGCAGTGCCT
TTCCAG-3; exon 5, 5-GTCTCCCCACAGTCCTC
ATC-3 and 5-GGCAGTGACAGGTTTCTCAAC-3;
exon 6, 5-GGCCCCCAAGCTATAGACAC-3 and
5-CCATGAATTGCTTTCTTTATTTG-3; exon 7,5-
TCATGCCCCTTTCTCTCATC-3 and 5-GCTCATG
GTTAAGGGGTTTG-3; exon 8, 5-TGCCTAGGA
ATGCAAATCAG-3 and 5-CCTTACCTGTCCTGG
ATGATG-3; exon 9, 5-TCAGCTCTGCACTGATGA
CAG-3 and 5-TGGCCAAATGTCTTTGGTTAC-3;
exon 10, 5-AACCACATTCAGGCTCCTTC-3 and
5-AGGTGCCAGGCTCTGTTATC-3; exon 11, 5-
GTCAGGATGCTTGCCAAATC-3 and 5-CACTG
CAGAAAGGACCTGAAC-3; and exon 12, 5-GG
GTGTCCTCTTCTGATTGG-3 and 5-CAGGTA
CACCGTCACAAGTCC-3 using a “touch down” pro-
gram with a starting annealing temperature of 72C (ex-
ons 4a, 5, and 10), decreasing every step by 0.7C for 24
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times and a next round of amplification with an annealing
temperature of 55C for 20 times. An annealing tempera-
ture of 60C was used for the exons 3, 4b, 8, and 9,
59C for exons 7, 11, and 12, and 57C for exon 6. PCR
products were purified using the Marligen Rapid PCR
Purification System (Ijamsville, MD, USA). Purified
PCR products were sequenced, using a Genetic Analyzer
3700 (Applied Biosystems) and resulting sequences were
evaluated with the Sequencher Software (Gene Codes,
Ann Arbor, MI, USA).
RESULTS
Clinical data
The three families presenting with UMOD mutations
included 12 living individuals affected with MCKD
(three in F524, three in F739 and six in F762) (Fig. 1).
Six of 12 also suffered from hyperuricemia (Table 1).
The patients presented with hyperuricemia between 17
and 59 years of age (Table 1). ESRD developed between
29 years and 60 years. Imaging by magnetic resonance
imaging (MRI) or ultrasound revealed in all families
suspicious results with small kidneys, decreased paren-
chyma, or cysts. Occasional small cysts were only visible
in three individuals by ultrasound (Table 1). Renal his-
tology in all cases was compatible with MCKD showing
microcysts in four out of 12 cases and in the others
dilated or atrophied tubules, global sclerosis, extensive
tubulointerstitial atrophy with fibrosis, and signs of
chronic diffuse inflammation (Table 1).
Linkage analysis
In 25 families with 224 individuals, haplotype analysis
for linkage to MCKD1 and MCKD2 was performed.
In one kindred (F762), we found significant linkage to
MCKD2. In six kindreds, significant linkage to chromo-
some 1 [logarithm of odds (LOD) score 3.0] or exclu-
sion of linkage to chromosme 16 was found. Linkage for
family F762 was previously published with a maxiumum
multipoint LOD score of 3.75 in the interval between
D16S3017 and D16S417 [20]. In 19 families too small for
significant linkage, haplotype analysis was compatible
with linkage to MCKD2.
Mutation analysis
We performed mutational analysis in affected individ-
uals from 19 families compatible with linkage to MCKD2
examining all 10 coding exons of the UMOD gene by
exon PCR and direct sequencing of the forward strands
of exon PCR products.
We used an “affecteds only” approach for definition
of the affected status of MCKD. Specifically, if diagnostic
data supported MCKD, the affected status was assumed.
If there was no data demonstrating the presence of
MCKD, the disease status was determined as unknown,
since there is age-related penetrance in MCKD. On this
basis, there was full-cosegregation of all found heterozy-
gous UMOD mutations and the affected status for MCKD.
In three of these families, novel mutations were de-
tected (Fig. 1). All three mutations were located in exon 4.
In family F524, a nucleotide exchange (C779A) was
found, resulting in the amino acid exchange Thr225Lys.
The mutation was identified in all three affected broth-
ers. Because I-1 in F524 is deceased, we cannot prove
that he had the same mutation. His treatment of 15 years
of dialysis makes his affected status very likely.
In family F739, a C849G mutation was detected, caus-
ing the amino acid exchange Cys248Trp. The mutation
in F762 is an inframe deletion/insertion at position 383
(383del12/ins9) that deletes five amino acids and inserts
four new amino acids.
Moreover, none of the mutations were found in 100
healthy controls. Therefore, our detected mutations are
unlikely to be common polymorphisms.
In exon 6, an additional substitution (G1477T,
Val458Leu) was found in two families that were compati-
ble with linkage to 16p12. Nevertheless, this substitution
was realized to be a new single nucleotide polymorphism
(SNP) because we detected it in four healthy controls
out of 100.
DISCUSSION
We detected three novel heterozygous mutations in
the UMOD gene, thereby confirming that UMOD is the
responsible gene for MCKD2. All detected mutations
are found in exon 4 of UMOD, thus underlining the
specific role of exon 4–encoded sequence in the genera-
tion of the MCKD2 renal phenotype.
In previous studies, abnormal localization of UMOD
protein in the interstitium in MCKD patients was shown,
suggesting UMOD as a candidate gene for MCKD [21].
By identifying three novel mutations, we confirmed the
UMOD gene as the responsible gene for MCKD2. All
mutations described here affect amino acids conserved
in the cow, mouse, and rat (Fig. 2). The mutation of
F762 (383del12/ins9) is positioned in a domain of known
function, the second calcium binding (cb) EGF-like do-
main. In F762, the cbEGF-like domain encoded by
UMOD exon 4 is affected by a loss of five amino acids
and their replacement by four new amino acids. Two of
the five amino acids involved by the mutation of F762
are highly conserved in evolution, including the lower
vertebrate zebrafish and the nematode Caenorhabditis
elegans, in genes encoding EGF binding domains (for
example, fibulin 1, an EGF containing extracellular ma-
trix protein). In a number of human diseases, including
Marfan syndrome, cerebral autodomal-dominant arte-
riopathy with subcortical infarcts and leukencephalopa-
thy (CADASIL), Alagille syndrome, protein S defi-
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Fig. 1. Mutations in the Uromodulin (UMOD) gene. The upper sequence shows the wild-type (WT) sequence and the lower sequence reveals
the mutation (MUT) in each family. The resulting amino acids are indicated below sequences. All mutations are located in exon 4. (A ) In affected
individuals of family F524, a heterozygous C779A substitution was detected resulting in a Thr225Lys amino acid exchange. (B ) Affected individuals
in family F739 showed a heterozygous C849G substitution, causing a Cys248Trp change. (C ) Affected subjects in F762 carried heterozygously a
12 bp deletion together with an insertion of nine nucleotides (383del12/ins9). The deleted nucleotides are indicated in underlined and bold. The
inserted nucleotides are shown in red. Because of this mutation five amino acids are replaced by four different ones. The pedigree was recently
published [20]. Arrows denote individuals in whom DNA was available for haplotype analysis.
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Fig. 2. Comparison of the amino acid conservation in exon 3 and 4 (in which all mutations up to now were found) through evolution, using the
CLUSTAL W (1.81) multiple sequence alignment software [27]. Shown is the amino acid sequence of the Uromodulin protein equivalent from
Homo sapiens, Bos taurus, Mus musculus, and Rattus norvegicus. To underline the high degree of conversation with the zymogen granule membrane
protein (GP2), the GP2 amino acid of Canis familiaris is indicated in the bottom row. The three calcium-binding endothelial growth facor (EGF)-
like domains are highlighted in light gray, dark gray, and black. These domains were found using the consensus sequence of calcium-binding EGF-
like domains in the NCBI Conserved Domain Database [28]. The amino acids affected by the mutations identified in patients with MCKD2 are
indicated by arrows. Amino acid numbering is shown on the right margin for Homo sapiens UMOD.
ciency, hemophilia B, and familial hypercholesterolaemia
missense mutations within cbEGF domains were found
[22]. Mutations in the Fibrillin-1 (FBN1) cause the Mar-
fan syndrome. FBN1 reveals an equivalent domain form-
ing a part of a calcium coordinating segment that stabi-
lizes the tertiary structure [23]. Tandem FBN1 cbEGF
domain pairs, when saturated with calcium, exhibit a rod-
like conformation [22]. In Marfan syndrome, missense
mutations in FBN1 have been described affecting the
same cbEGF domain as the mutation of F762 (383del12/
ins9) [24, 25]. Smallridge et al [22] distinguished muta-
tions within cbEGF domains as (1) mutations affecting
cysteine residues and thereby disrupting disulphide
bonds and (2) mutations affecting residues in the cal-
cium-binding consensus sequence, which are likely to
reduce calcium-binding affinity. As a consequence of the
383del12/ins9 mutation a cysteine is also affected, but
the reason for the resulting impaired function remains
theoretical because the importance of the four other
replaced amino acids (ValProGlyGlu) is unclear.
The Thr225Lys mutation of F524 and the Cys248Trp
mutation of F739 are located in a region of unknown
function that is also encoded by exon 4. Hart et al [10] and
Turner et al [17], repectively, also found two mutations in
this region of exon 4, outside the known cbEGF-like
domain. Interestingly, this region shows an identity of
56% with GP2, another ZP domain-containing protein.
All three mutations found are not only conserved in the
above-mentioned animals but also in this conserved part
of GP2 of Canis familiaris. Two of these mutations (Cys-
248Trp in F739, 383del12/ins9 in F762) involve cysteine
residues, which are highly conserved in the UMOD pro-
tein throughout evolution including C. elegans (Fig. 2).
UMOD contains 48 cysteine residues per monomer form-
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ing 24 intramolecular disulfide bonds. The amino acid
changes in F739 and F762 are therefore expected to
change the molecular conformation through impaired
intra- or intermolecular disulphide bond formation. The
high cysteine content of THP and correct formation of
the disulphide bonds were suspected to be the rate lim-
iting step for the export of the premature THP out the
endoplasmatic reticulum and that this regulates the effi-
ciency of THP maturation [11].
Impaired disulphide binding is well known as a reason
for other disorders, for example, diabetes insipidus cen-
tralis with a less stable vasopressin precursor, which accu-
mulates in the endoplasmic reticulum [26]. The muta-
tions we found are very likely to cause MCKD2 in these
patients, even if none of them is a frameshift or a non-
sense mutation. Also Hart et al [10] and Turner et al
[17] did not detect any frameshift or nonsense mutation,
which would cause a truncated protein. In addition, and
surprisingly, all up to now identified mutations with the
exception of one mutation at the beginning of the neigh-
boring exon 5 are located in exon 4. All mutations take
place in front of the ZP domain. The N-terminal half of
exon 4 encodes the three known calcium-binding EGF-
like domains [16]. The C-terminal part of exon 4 includes
a nine amino acid long immunoglobulin light chain–
binding domain [14], which has not been affected by any
mutation up to now. However, it seems that exon 4 plays
an important role in the function of UMOD and that
heterozygous mutations in this exon lead to the specific
phenotype of MCKD2.
The clinical presentation of the phenotype has to be
evaluated very carefully since renal cysts in imaging (only
three of 12 affected individuals) and hyperuricemia (six
of 12 affected individuals) do not occur in all of the
patients. In all affected individuals, renal insufficiency
(creatinine clearance 60 mL/min/1.73 m2) was diag-
nosed. The age of onset is varied between 17 and 59 years
of age. Hart et al [10] also described a kindred, in which
the vast majority but not all affected individuals have
hyperuricemia. This underlines the heterogeneity of the
phenotype and might show that neither hyperuricemia
nor cysts are an obligatory feature of the clinical presen-
tation. At the moment, a significant genotype/phenotype
correlation is not possible due to the limited number of
different mutations detected so far.
Finally, it was surprising to us to find only three muta-
tions in 19 families, which were compatible with linkage
to 16p12. This may be explained by the small number
of affected persons in most families, possibly resulting
in false positive linkage result in an autosomal-dominant
disease. Alternatively, a second gene for FJHN and
MCKD2 might exist in the more centromeric region of
UMOD in the region described by Kamatani et al [7]
and which excludes the UMOD gene. Reports about
additional mutations in MCKD2 and studies concerning
the function of the UMOD protein will help to clarify
the role of exon 4 for the pathogenesis of MCKD.
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